Pfizer and BioNTech’s Covid-19 vaccine shows promise in Phase 3 interim analysis
The vaccine candidate was more than 90% effective in preventing Covid-19 in participants without prior SARS-CoV-2 infection
We use them to give you the best experience. If you continue using our website, we'll assume that you are happy to receive all cookies on this website.
ContinueLearn More X
10 Nov 20
The vaccine candidate was more than 90% effective in preventing Covid-19 in participants without prior SARS-CoV-2 infection
10 Nov 20
NVX-CoV2373 is being studied under Phase 3 clinical trial in the UK, with additional trials planned in the…
09 Nov 20
The acquisition will help Novo Nordisk expand its portfolio of oral biologic pipeline assets by using Emisphere’s drug…
06 Nov 20
The acquisition will strengthen Merck’s oncology portfolio with investigational antibody-drug conjugate VLS-101 for blood cancers and solid tumours
PharmaceuticalsActive Pharmaceutical Ingredients and Intermediates
06 Nov 20
The maintenance treatment using the drug regimen reduced the risk of disease progression or death by 67%, and…
05 Nov 20
Novavax will supply NVX-CoV2373 to Australia from the first half of 2021, subject to Phase 3 clinical trials…
05 Nov 20
The partnership will develop advanced analytical solutions and deliver training to address the current requirements of the biopharmaceutical…
PharmaceuticalsConsulting, Training and Other Pharmaceutical Services
04 Nov 20
Vupanorsen is an investigational antisense therapy, discovered by Ionis Pharmaceuticals and co-developed by Ionis and its subsidiary Akcea…
03 Nov 20
Tecentriq plus Avastin is the first and only approved cancer regimen for unresectable hepatocellular carcinoma (HCC) in Europe
02 Nov 20
Adakveo is claimed to be the first targeted sickle cell disease therapy for prevention of recurrent vaso-occlusive crises…